Trial Information
Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China
Inclusion Criteria:
- Must be Multiple Myeloma Proved by Laboratory Tests
- Must have the ability to observe the efficacy and events
- Patient must have the ability to understand and willingness to provide written
informed consent in the study and any related procedures being performed
Exclusion Criteria:
- If have uncontrolled intercurrent illness including ongoing or active infection,heart
failure,unstable angina pectoris,or psychiatric illness/social situations that study
requirements
- If have severe side-effects on bortezomib
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
overall survival rates
Outcome Time Frame:
three years
Safety Issue:
Yes
Principal Investigator
Fu chengcheng, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
First Affiliated Hospital,Soochow University
Authority:
China: Ethics Committee
Study ID:
chengchengfu
NCT ID:
NCT01812096
Start Date:
November 2012
Completion Date:
December 2016
Related Keywords:
- Multiple Myeloma Proved by Laboratory Tests
- multiple myeloma
- bortezomib
- Subcutaneous
- Multiple Myeloma
- Neoplasms, Plasma Cell